BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms

Key Points

• Tafamidis IP trial overhang: BridgeBio says a late‑April U.S. trial on the Form I tafamidis patent is the main market overhang, and the company believes Pfizer has “very, very strong” infringement and validity arguments with a ruling that could effectively determine generic entry timing (Kumar called a patent hold through 2035 “highly probable”).
• Atrubie commercial momentum and market opportunity: Management reports improving launch momentum as Atrubie adoption expands beyond academic centers into high‑volume heart‑failure practices, highlighting statistically significant subgroup data and projecting the ATTR cardiomyopathy market could become a $20 billion opportunity given persistent underdiagnosis.
• Pipeline wins and launch readiness: After three recent Phase 3 readouts (ADH1, LGMD2I, achondroplasia), BridgeBio says it has built commercial infrastructure, holds “well over $1 billion” cash, expects future launches to be materially cheaper, and could launch ADH1 and LGMD2I in the first half of next year.

BridgeBio Pharma NASDAQ: BBIO CEO Neil Kumar outlined the company’s recent clinical progress, commercial momentum, and near-term regulatory plans during a fireside chat at TD Cowen’s 46th Annual Healthcare Conference, while also addressing investor focus on a pending intellectual property trial related to tafamidis.

Stock pullback and the tafamidis IP overhang

Kumar said the company has “noted the pullback” in BridgeBio’s share price and described what he viewed as a disconnect between intrinsic value and current trading levels. He pointed to the company’s “last three phase threes,” citing positive Phase 3 readouts in ADH1, LGMD2I, and achondroplasia, which he said “all met or beat” expectations.

He also said feedback BridgeBio has heard from the market suggests the primary overhang is the upcoming “TAF IP” trial, which he noted is scheduled for late April. Kumar said BridgeBio believes Pfizer has “very, very strong arguments” on both infringement and validity. He discussed analytical methods he said can detect “Form I” (including solid-state NMR, X-ray diffraction, and Raman spectroscopy) and argued that U.S. validity standards are high. He added that in the U.S. the forthcoming ruling would be the key decision, stating there would be “no appeals process after that.”

In the discussion, Kumar and the moderator reviewed several potential outcomes, including scenarios involving generic entry timing and settlement windows. Kumar said the scenario in which the Form I tafamidis IP holds through 2035 is “highly probable,” while acknowledging that others may assess probabilities differently.

Atrubie launch: growth drivers and market expansion

On the commercial trajectory for Atrubie (acoramidis), Kumar characterized launch performance as “multifactorial” and said he was encouraged by what he described as improving momentum over time, including “growing growth” quarter over quarter. He attributed this to better patient identification across the field, including expansion beyond academic medical centers into high-volume heart failure practices, and noted that he believes a significant portion of ATTR cardiomyopathy patients remain undiagnosed in the U.S.

He also pointed to additional clinical data as a contributor to adoption, including what he described as early separation trends and results in certain subpopulations. Kumar highlighted variant population data he cited as a 0.41 hazard ratio with statistical significance, and said Atrubie “works both in the context of AFib and in the context of non-AFib,” which he argued could simplify prescribing.

Asked about the total market opportunity, Kumar said he believes the ATTR cardiomyopathy market has “a real chance of becoming a $20 billion market,” referencing his view that studies suggest at least 12% of heart failure patients have ATTR cardiomyopathy.

On competition, Kumar said much of BridgeBio’s progress comes down to its own execution, while also suggesting that sponsor activity can expand the overall category. He cited Pfizer’s publications on serum transthyretin (TTR) as reinforcing physician education, and said that’s beneficial to the class.

Ex-U.S. royalties from Europe launch with Bayer

Kumar also discussed Bayer’s European launch of Beontra, stating that BridgeBio should begin to see a “meaningful” P&L contribution this year, citing “high royalties” and describing Bayer’s early penetration as strong in certain markets, including Germany.

Three Phase 3 readouts: launch planning, timelines, and market views

BridgeBio expects upcoming product launches to be “materially cheaper” than the Atrubie launch, Kumar said, because the company has already built commercial infrastructure for distribution, patient services, market access, and training. He added that BridgeBio has “well over $1 billion” on the balance sheet and said R&D spending should be “flat to declining” as large Phase 3 programs roll off, while commercial spend may increase incrementally.

For field force sizing, Kumar said ATTR requires a much larger footprint than the rare disease programs such as LGMD2I or ADH1, describing those as “small field forces.” He said the company has hired commercial leaders and deployed medical affairs for each upcoming program, and that it is conducting appropriate early work such as pricing-related research while awaiting approvals.

• Achondroplasia (infigratinib): Kumar referenced prior market research suggesting potential preference share of 65%, while noting some key opinion leaders have suggested higher. He said current market penetration is roughly 25% and cited market research indicating about 35% of U.S. patients may be needle-phobic, framing the oral option as a potential driver to expand the addressable market and take share based on efficacy, safety, and convenience. On hypochondroplasia, he said BridgeBio expects best-in-class efficacy at a dose it considers safe and stated the market could be similarly sized to achondroplasia, though less well-defined. He said data in hypochondroplasia are expected later this year and Phase 3 could start next year. When asked about combined market potential for achondroplasia and hypochondroplasia, Kumar said $5 billion was a “rough sense,” while emphasizing pricing has not been discussed.
• LGMD2I (BBP-418): Kumar said the company believes there may be roughly 1,200–1,300 U.S. patients and suggested many are already identified through muscular dystrophy clinics and natural history work. He said the company expects a premium-priced launch and aims to serve identified patients quickly. He said FDA discussions supported pursuing a traditional full approval pathway, citing consistency of effects across functional outcomes and across subpopulations as important to the agency.
• ADH1 (encaleret): Kumar described a larger genetic prevalence (10,000–12,000 in the U.S.) but said identified hyper-symptomatic patients may currently number 2,000–3,000. He discussed a genetic testing program targeting roughly 130 known hyperactivating calcium-sensing receptor mutations, offering a panel “at cost” to help physicians better understand underlying biology in patients classified as hypoparathyroidism. Kumar suggested ADH1 could be a slower-build launch than LGMD2I but reach similar peak sales over time.

Kumar said that, based on filing timelines, BridgeBio could be positioned to launch both ADH1 and LGMD2I programs in the first half of next year, while noting achondroplasia timing could also potentially fall in that window but remains to be seen.

Pipeline priorities and a GondolaBio EPP program update

Looking beyond near-term launches, Kumar said the company is working across internal and affiliated efforts, including GondolaBio, and referenced programs in erythropoietic protoporphyria (EPP), CMT1A, and alpha-1 antitrypsin deficiency, as well as multiple development candidates.

On EPP, Kumar described GondolaBio’s approach as inhibiting the ABCG2 transporter to block egress of protoporphyrin IX (PPIX) from red blood cells. He said a Phase 2 showed rapid PPIX reductions “up to 80%” and suggested the maximum reduction could occur within two days. He also said the company believes the mechanism may affect liver involvement based on animal models, and that an end-of-Phase 2 meeting is expected in about a month and a half to help determine the path forward.

In closing, Kumar said that in recent weeks he believes Atrubie has become “underappreciated” by investors due to the tafamidis IP overhang, arguing the brand is growing in a market with significant unmet need and continued clinical data generation.

About BridgeBio Pharma NASDAQ: BBIO

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.